Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2/3 1Phase 1/2 1

Status

Completed 7Recruiting 5Unknown 3Terminated 2Not yet recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 16NIH 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gastroenteropancreatic Neuroendocrine Tumors 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Sirolimus × Clear all
NCT06528301 2026-05-28

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Umoja Biopharma

Phase 1 Recruiting
106 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT07241936 2025-11-28

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Recruiting
444 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Olema Pharmaceuticals, Inc.

Phase 1 Recruiting
190 enrolled
Breast

Breast Neoplasms

NCT06743503 2025-09-18

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

Nanjing IASO Biotechnology Co., Ltd.

Phase 1 Recruiting
70 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡